Related Experiment Video
Updated: Aug 11, 2026

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
Published on: April 11, 2025
Utility of ECG-Vision for Surveillance of Left Ventricular Dysfunction in Patients With Hypertrophic Cardiomyopathy
Aakash Bavishi1, John Fritzlen2, Marybeth Soutar3
1University of Illinois-Chicago (A.B.).
Insights
Artificial intelligence (AI)-enabled ECGs show promise in predicting left ventricular systolic dysfunction (LVSD) in hypertrophic cardiomyopathy patients on mavacamten. This AI tool could reduce the need for frequent echocardiograms, improving access to care.
Area of Science:
- Cardiology
- Artificial Intelligence
- Medical Diagnostics
Background:
- Obstructive hypertrophic cardiomyopathy (HCM) requires frequent monitoring for left ventricular systolic dysfunction (LVSD) using transthoracic echocardiograms (TTEs).
- Current monitoring methods can be burdensome and limit access, particularly in rural or underserved areas.
- Mavacamten is a myosin inhibitor used to treat obstructive HCM.
Purpose of the Study:
- To evaluate the performance of an artificial intelligence (AI)-enabled ECG tool in predicting LVSD in patients with obstructive HCM treated with mavacamten.
- To assess the potential of AI-ECG as an alternative or adjunctive tool to TTE for LVSD monitoring.
Main Methods:
- A cohort of 147 patients with obstructive HCM initiated on mavacamten underwent paired ECG and TTE at baseline and follow-up.
- A validated AI-enabled ECG algorithm was used to predict the probability of LVSD (defined as left ventricular ejection fraction <50%).
- Sensitivity, specificity, positive predictive value, negative predictive value, and AUC were calculated, accounting for repeated measures.
Main Results:
- The AI-enabled ECG demonstrated high sensitivity (100%) and negative predictive value (100%) for detecting LVSD at a 20% probability threshold.
- The area under the curve (AUC) was 0.94, indicating strong predictive performance.
- Patient-level classification concordance between AI-ECG and TTE was 86%.
Conclusions:
- AI-enabled ECG tools show high sensitivity and NPV for detecting LVSD in obstructive HCM patients on mavacamten.
- While estimates were imprecise due to infrequent LVSD events, findings support AI-ECG as a potential adjunctive triage tool.
- Prospective, multicenter validation is recommended to confirm these exploratory findings.
Background:
Frequent transthoracic echocardiograms (TTEs) are required to monitor for left ventricular systolic dysfunction (LVSD) in patients with obstructive hypertrophic cardiomyopathy receiving myosin inhibitors. This requirement may be cumbersome and limit access in underserved and rural areas. The objective of this study was to evaluate the performance of an artificial intelligence (AI)-enabled ECG tool in predicting LVSD in hypertrophic cardiomyopathy patients on mavacamten.
Methods:
At Morristown Medical Center/Atlantic Health, 147 patients initiated on mavacamten between June 2022 and June 2025 underwent ECGs and TTEs at baseline and clinically available follow-up visits. A validated AI-enabled ECG algorithm predicted the probability of LVSD. Sensitivity, specificity, negative predictive value, positive predictive value, and area under the curve were calculated for left ventricular ejection fraction <50%, with CIs accounting for repeated paired ECG-TTE observations within patients.
Results:
In 147 patients, mean age was 65±14 years; 44% were male. Among 453 paired ECG-TTE observations, 8 LVSD event observations occurred. At an AI probability threshold of 20%, sensitivity was 100% (95% CI, 68%-100%), specificity was 75% (95% CI, 69%-82%), positive predictive value was 7% (95% CI, 3%-11%), and negative predictive value was 100% (95% CI, 99%-100%). The area under the curve was 0.94 (95% CI, 0.90-0.98). Patient-level classifications between AI-enabled ECG and echo-confirmed LVSD were concordant in 127 of 147 patients (86%), inconclusive in 17 of 147 (12%), and discordant in 3 of 147 (2%).
Conclusions:
In this single-center exploratory cohort of patients with obstructive hypertrophic cardiomyopathy receiving mavacamten, ECG-Vision left ventricular demonstrated high observed sensitivity and negative predictive value for TTE-defined LVSD, although estimates were imprecise because LVSD events were infrequent. These findings support prospective multicenter validation of AI-enabled ECG as a potential adjunctive triage tool.
More Related Videos
07:38Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension
Published on: January 20, 2023
10:33Assessment of Right Ventricular Structure and Function in Mouse Model of Pulmonary Artery Constriction by Transthoracic Echocardiography
Published on: February 3, 2014
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Imaging Studies for Cardiovascular System I:Echocardiography
Indications: Echocardiography is utilized to diagnose heart failure, valve disorders, and myocardial infarction. It also assesses cardiac structures' size, shape, and motion, evaluates...
Pulse rhythm
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac muscle...
Cardiomyopathy V: Interprofessional Care
Mitral Valve Prolapse II: Assessment and Management
Electrocardiogram
Three major waveforms are present in a typical ECG recording: the P wave, the QRS complex, and the T...